243 related articles for article (PubMed ID: 25525034)
1. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
[TBL] [Abstract][Full Text] [Related]
2. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
Sage EK; Kolluri KK; McNulty K; Lourenco Sda S; Kalber TL; Ordidge KL; Davies D; Gary Lee YC; Giangreco A; Janes SM
Thorax; 2014 Jul; 69(7):638-47. PubMed ID: 24567297
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.
Yang X; Du J; Xu X; Xu C; Song W
J Immunol Res; 2014; 2014():318098. PubMed ID: 24971369
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
[TBL] [Abstract][Full Text] [Related]
7. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
[TBL] [Abstract][Full Text] [Related]
8. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
9. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
10. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
Xia P; Wang W; Bai Y
Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
[TBL] [Abstract][Full Text] [Related]
11. TRAIL-overexpressing Adipose Tissue-derived Mesenchymal Stem Cells Efficiently Inhibit Tumor Growth in an H460 Xenograft Model.
Un Choi Y; Yoon Y; Jung PY; Hwang S; Hong JE; Kim WS; Sohn JH; Rhee KJ; Bae KS; Eom YW
Cancer Genomics Proteomics; 2021; 18(4):569-578. PubMed ID: 34183389
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.
Mohr A; Lyons M; Deedigan L; Harte T; Shaw G; Howard L; Barry F; O'Brien T; Zwacka R
J Cell Mol Med; 2008 Dec; 12(6B):2628-43. PubMed ID: 18373740
[TBL] [Abstract][Full Text] [Related]
13. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
14. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
Yoon N; Park MS; Peltier GC; Lee RH
Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo.
Salmasi Z; Hashemi M; Mahdipour E; Nourani H; Abnous K; Ramezani M
Biotechnol Prog; 2020 Nov; 36(6):e3025. PubMed ID: 32410328
[TBL] [Abstract][Full Text] [Related]
16. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
17. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
[TBL] [Abstract][Full Text] [Related]
19. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
